Exact Mass: 223.1369

Exact Mass Matches: 223.1369

Found 31 metabolites which its exact mass value is equals to given mass value 223.1369, within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error 0.0002 dalton.

1-Benzyl-1,2,3,4-tetrahydroisoquinoline

1,2,3,4-tetrahydro-1-(Phenylmethyl)isoquinoline hydrochloride

C16H17N (223.1361)


1-benzyl-1,2,3,4-tetrahydroisoquinoline (1BnTIQ) as a possible PD-eliciting neurotoxin and evaluated its characteristics relevant to Parkinson disease (PD). 1BnTIQ exist in mammals and is proposed as possible PD-eliciting neurotoxin. PD is believed to be induced by the interaction of genetic predisposition and environmental factors, and a type of neurotoxin is proposed to be one of the environmental factors. 1BnTIQ inhibits [3H] dopamine uptake in HEK293 cells which stably express dopamine transporter. 1BnTIQ also inhibits NADH-ubiquinone oxidoreductase (complex I) in the mitochondrial respiratory chain. 1BnTIQ decreases the dopamine content in the mesencephalon in both dose- and time-dependent manners and it irreversibly reduced the dopamine content. Furthermore, it causes morphological changes in tyrosine hydroxylase-positive cells in the mesencephalon and reduced the number of cells. (PMID 12440154) [HMDB] 1-benzyl-1,2,3,4-tetrahydroisoquinoline (1BnTIQ) as a possible PD-eliciting neurotoxin and evaluated its characteristics relevant to Parkinson disease (PD). 1BnTIQ exist in mammals and is proposed as possible PD-eliciting neurotoxin. PD is believed to be induced by the interaction of genetic predisposition and environmental factors, and a type of neurotoxin is proposed to be one of the environmental factors. 1BnTIQ inhibits [3H] dopamine uptake in HEK293 cells which stably express dopamine transporter. 1BnTIQ also inhibits NADH-ubiquinone oxidoreductase (complex I) in the mitochondrial respiratory chain. 1BnTIQ decreases the dopamine content in the mesencephalon in both dose- and time-dependent manners and it irreversibly reduced the dopamine content. Furthermore, it causes morphological changes in tyrosine hydroxylase-positive cells in the mesencephalon and reduced the number of cells. (PMID 12440154). D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists

   

3,3-Diphenylpyrrolidine

3,3-Diphenylpyrrolidine

C16H17N (223.1361)


   

4-Dimethylaminostilbene

N,N-dimethyl-4-(2-phenylethenyl)aniline

C16H17N (223.1361)


   

(2S,5S)-2,5-Diphenylpyrrolidine

(2S,5S)-2,5-Diphenylpyrrolidine

C16H17N (223.1361)


   

2-tert-butyl-9H-carbazole

2-tert-butyl-9H-carbazole

C16H17N (223.1361)


   

4-Dimethylaminostilbene

N,N-Dimethyl-p-styrylaniline

C16H17N (223.1361)


   

(+/-)-TETRAHYDROPAPAVEROLINEHYDROBROMIDE

(+/-)-TETRAHYDROPAPAVEROLINEHYDROBROMIDE

C13H18FNO (223.1372)


   

1H-Benz[f]isoindole,2-cyclopropyl-2,3-dihydro-6-methyl-(9CI)

1H-Benz[f]isoindole,2-cyclopropyl-2,3-dihydro-6-methyl-(9CI)

C16H17N (223.1361)


   

9-ethyl-3,6-dimethylcarbazole

9-ethyl-3,6-dimethylcarbazole

C16H17N (223.1361)


   

4-[(5-fluoro-2-methoxyphenyl)methyl]piperidine

4-[(5-fluoro-2-methoxyphenyl)methyl]piperidine

C13H18FNO (223.1372)


   

9H-Carbazole, 9-butyl-

9H-Carbazole, 9-butyl-

C16H17N (223.1361)


   

5-aminomethyl-dibenzosuberane

5-aminomethyl-dibenzosuberane

C16H17N (223.1361)


   

(3R,4R)-4-(4-Fluorophenyl)-3-piperidinemethanol

(3R,4R)-4-(4-Fluorophenyl)-3-piperidinemethanol

C13H18FNO (223.1372)


   

(2R,5R)-2,5-Diphenylpyrrolidine

(2R,5R)-2,5-Diphenylpyrrolidine

C16H17N (223.1361)


   

N-PHENYL-1,2,3,4-TETRAHYDRO-2-AMINONAPHTHALENE

N-PHENYL-1,2,3,4-TETRAHYDRO-2-AMINONAPHTHALENE

C16H17N (223.1361)


   

N-benzyl-2,3-dihydro-1H-inden-1-amine

N-benzyl-2,3-dihydro-1H-inden-1-amine

C16H17N (223.1361)


   

(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-yl)methanamine

(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-yl)methanamine

C16H17N (223.1361)


   
   

4-[2-(4-Fluorophenoxy)ethyl]piperidine

4-[2-(4-Fluorophenoxy)ethyl]piperidine

C13H18FNO (223.1372)


   

1-benzhydrylazetane

1-benzhydrylazetane

C16H17N (223.1361)


   

4-(3-FLUORO-4-METHOXY-BENZYL)-PIPERIDINE

4-(3-FLUORO-4-METHOXY-BENZYL)-PIPERIDINE

C13H18FNO (223.1372)


   

2-[1,1-BIPHENYL]-2-YL-PYRROLIDINE

2-[1,1-BIPHENYL]-2-YL-PYRROLIDINE

C16H17N (223.1361)


   

UNII:QRA30YT0AV

UNII:QRA30YT0AV

C13H18FNO (223.1372)


   

(S)-2-(2-PHENYLPHENYL)PYRROLIDINE

(S)-2-(2-PHENYLPHENYL)PYRROLIDINE

C16H17N (223.1361)


   

(S)-2-(4-PHENYLPHENYL)PYRROLIDINE

(S)-2-(4-PHENYLPHENYL)PYRROLIDINE

C16H17N (223.1361)


   

4,5-diethylpyrrolo[1,2-a]quinoline

4,5-diethylpyrrolo[1,2-a]quinoline

C16H17N (223.1361)


   

2-(4-Biphenylyl)pyrrolidine

2-(4-Biphenylyl)pyrrolidine

C16H17N (223.1361)


   

(3S,4R)-4-(4-Fluorophenyl)-3-hydroxymethyl-1-methylpiperidine

(3S,4R)-4-(4-Fluorophenyl)-3-hydroxymethyl-1-methylpiperidine

C13H18FNO (223.1372)


   

1H-Indole,1-(2,5-dimethylphenyl)-2,3-dihydro-(9CI)

1H-Indole,1-(2,5-dimethylphenyl)-2,3-dihydro-(9CI)

C16H17N (223.1361)


   

1-Benzyl-1,2,3,4-tetrahydroisoquinoline

Isoquinoline,1,2,3,4-tetrahydro-1-(phenylmethyl)-

C16H17N (223.1361)


D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists

   

Benzyltetrahydroisoquinoline

Benzyltetrahydroisoquinoline

C16H17N (223.1361)